The PE Ratio as of November 2024 (TTM) for Eliem Therapeutics, Inc. (ELYM) is -2.30

According to Eliem Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.30. This represents a change of -58.14% compared to the average of -5.50 of the last 4 quarters.

Eliem Therapeutics, Inc. (ELYM) Historical PE Ratio (quarterly & annually)

How has ELYM PE Ratio performed in the past?

The mean historical PE Ratio of Eliem Therapeutics, Inc. over the last ten years is -31.31. The current -2.30 PE Ratio has changed 635.18% with respect to the historical average. Over the past ten years (40 quarters), ELYM's PE Ratio was at its highest in in the March 2023 quarter at -0.91. The PE Ratio was at its lowest in in the June 2020 quarter at -28.42.

Eliem Therapeutics, Inc. (ELYM) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Eliem Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Eliem Therapeutics, Inc. (ELYM) Average PE Ratio

How has ELYM PE Ratio performed in the past?

The current PE Ratio of Eliem Therapeutics, Inc. (ELYM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Eliem Therapeutics, Inc. (ELYM) PE Ratio vs. Peers

How is ELYM’s PE Ratio compared to its peers?

Eliem Therapeutics, Inc.’s PE Ratio is less than PMV Pharmaceuticals, Inc. (-1.61), less than MediciNova, Inc. (-0.04), greater than Pharvaris N.V. (-8.69), less than PepGen Inc. (-1.65), greater than Anebulo Pharmaceuticals, Inc. (-4.78), greater than Rezolute, Inc. (-4.94), less than HCW Biologics Inc. (-0.78), greater than Molecular Partners AG (-2.50), less than Aerovate Therapeutics, Inc. (-0.91), greater than Adagene Inc. (-3.02), greater than Acrivon Therapeutics, Inc. Common Stock (-3.24), less than AN2 Therapeutics, Inc. (-0.66), greater than Cyteir Therapeutics, Inc. (-9.12), less than Pardes Biosciences, Inc. (-1.36), less than Shattuck Labs, Inc. (-0.69), greater than Champions Oncology, Inc. (-18.21), less than Century Therapeutics, Inc. (-0.79),

Build a custom stock screener for Eliem Therapeutics, Inc. (ELYM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eliem Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Eliem Therapeutics, Inc. (ELYM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Eliem Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.